Literature DB >> 31101617

Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.

Long Fu Xi1, Mark Schiffman2, James P Hughes3, Denise A Galloway4, Laura A Koutsky5, Nancy B Kiviat6.   

Abstract

BACKGROUND: Epidemiologic data addressing clinical relevance of viral load fluctuation of oncogenic types other than human papillomavirus (HPV) types 16 and 18 are limited.
METHODS: A type-stratified set of infections by non-HPV16/18 oncogenic types that were detected at ≥2 visits was randomly selected from women who were enrolled in a clinical trial and followed every 6 months for 2 years for detection of HPV and cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3). Type-specific viral load was measured on both first and last HPV-positive cervical swab samples.
RESULTS: CIN2/3 was initially confirmed at the last HPV-positive visit for 67 of 439 infections. The increase in risk of CIN2/3 was associated with high, relative to low, viral load at both first and last positive visits [ORadjusted = 3.67; 95% confidence interval (CI), 1.19-11.32] and marginally associated with a change of viral load from low to high levels (ORadjusted = 3.15; 95% CI, 0.96-10.35) for infection by species group alpha-9 non-HPV16 oncogenic types but not species group alpha-5-7 non-HPV18 oncogenic types. Among women with an initial diagnosis of CIN2/3 at the first positive visit, CIN2/3 was more frequently redetected at the last positive visit for infections with, compared with without, high DNA load of species group alpha-9 non-HPV16 oncogenic types at both visits (P exact = 0.04).
CONCLUSIONS: In agreement with data on baseline viral load, the viral load change-associated risk of CIN2/3 differs by HPV species groups. IMPACT: These findings underscore the importance of distinguishing species groups in future studies of clinical relevance of HPV DNA load. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31101617      PMCID: PMC6679727          DOI: 10.1158/1055-9965.EPI-18-0802

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  A covariance estimator for GEE with improved small-sample properties.

Authors:  L A Mancl; T A DeRouen
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.

Authors:  N F Schlecht; S Kulaga; J Robitaille; S Ferreira; M Santos; R A Miyamura; E Duarte-Franco; T E Rohan; A Ferenczy; L L Villa; E L Franco
Journal:  JAMA       Date:  2001-12-26       Impact factor: 56.272

3.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  Role of human papillomavirus (HPV) testing in the follow-up of patients after treatment for cervical precancerous lesions.

Authors:  Zoltán Hernádi; Krisztina Szoke; Tamás Sápy; Zoárd T Krasznai; Györgyike Soós; György Veress; Lajos Gergely; József Kónya
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-02-01       Impact factor: 2.435

5.  Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study.

Authors:  N Ylitalo; P Sørensen; A M Josefsson; P K Magnusson; P K Andersen; J Pontén; H O Adami; U B Gyllensten; M Melbye
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

6.  Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance.

Authors:  Mark van Duin; Peter J F Snijders; Henri F J Schrijnemakers; Feja J Voorhorst; Lawrence Rozendaal; Marielle A E Nobbenhuis; Adriaan J C van den Brule; René H M Verheijen; Theo J Helmerhorst; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

7.  ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

Authors:  M Schiffman; M E Adrianza
Journal:  Acta Cytol       Date:  2000 Sep-Oct       Impact factor: 2.319

8.  Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ.

Authors:  Martin Moberg; Inger Gustavsson; Ulf Gyllensten
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

9.  Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization.

Authors:  Angel Chao; Cheng-Tao Lin; Swei Hsueh; Hung-Hsueh Chou; Ting-Chang Chang; Min-Yu Chen; Chyong-Huey Lai
Journal:  Am J Obstet Gynecol       Date:  2004-04       Impact factor: 8.661

10.  Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions.

Authors:  V Houfflin Debarge; P Collinet; D Vinatier; A Ego; A Dewilde; F Boman; J L Leroy
Journal:  Gynecol Oncol       Date:  2003-09       Impact factor: 5.482

View more
  2 in total

1.  The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

2.  Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol.

Authors:  Maribel Almonte; Raúl Murillo; Gloria Inés Sánchez; Paula González; Annabelle Ferrera; María Alejandra Picconi; Carolina Wiesner; Aurelio Cruz-Valdez; Eduardo Lazcano-Ponce; Jose Jerónimo; Catterina Ferreccio; Elena Kasamatsu; Laura Mendoza; Guillermo Rodríguez; Alejandro Calderón; Gino Venegas; Verónica Villagra; Silvio Tatti; Laura Fleider; Carolina Terán; Armando Baena; María de la Luz Hernández; Mary Luz Rol; Eric Lucas; Sylvaine Barbier; Arianis Tatiana Ramírez; Silvina Arrossi; María Isabel Rodríguez; Emmanuel González; Marcela Celis; Sandra Martínez; Yuly Salgado; Marina Ortega; Andrea Verónica Beracochea; Natalia Pérez; Margarita Rodríguez de la Peña; María Ramón; Pilar Hernández-Nevarez; Margarita Arboleda-Naranjo; Yessy Cabrera; Brenda Salgado; Laura García; Marco Antonio Retana; María Celeste Colucci; Javier Arias-Stella; Yenny Bellido-Fuentes; María Liz Bobadilla; Gladys Olmedo; Ivone Brito-García; Armando Méndez-Herrera; Lucía Cardinal; Betsy Flores; Jhacquelin Peñaranda; Josefina Martínez-Better; Ana Soilán; Jacqueline Figueroa; Benedicta Caserta; Carlos Sosa; Adrián Moreno; Juan Mural; Franco Doimi; Diana Giménez; Hernando Rodríguez; Oscar Lora; Silvana Luciani; Nathalie Broutet; Teresa Darragh; Rolando Herrero
Journal:  BMJ Open       Date:  2020-05-24       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.